Annales de cardiologie et d'angeiologie · 2025
[Temps passé dans l'intervalle thérapeutique dans la maladie veineuse thrombo-embolique : intérêt dans la prévention des complications].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rachdi Imène, Ben Brahim Mariem, Somai Mehdi, Arbaoui Ibrahim, Ben Dhaou Besma, Boussema Fatma, Daoud Fatma, Aydi Zohra
Аннотация
BACKGROUND: Vitamin K antagonists (VKAs) are the most commonly prescribed drug for the treatment of venous thromboembolism (VTE). Our study's aim was to evaluate the role of Time in Therapeutic Range (TTR) in preventing thrombotic and hemorrhagic complications in patients treated by VKAs for VTE.
METHODS: Our study is prospective, descriptive, and longitudinal, including patients admitted to an Internal Medicine department in Tunis, during a 9-month period. One hundred patients diagnosed with VTE confirmed with imaging and treated with VKAs were included. TTR was calculated using Rosendaal's method through a free software INR PRO©.
RESULTS: The mean age of patients was 59.4 ± 16.7 years. Sex-ratio was 1.5. VKAs were mainly prescribed for deep venous thromboses (57%). Cancer was the most common etiology (26%). The mean follow-up period was 5.3 months. The mean TTR was 36.1±22.5%. Twenty-seven percent of patients had a TTR>50%. We noted 25% of hemorrhagic events and 15% of thromboembolic recurrence. A TTR<50% was correlated with hemorrhagic complications (p=0.02), but not with thrombotic ones (p = 0.224).
CONCLUSION: Our results outline the necessity of implementing adequate tools to improve anticoagulation in our population. Implementing TTR as a quality assessment tool for anticoagulation will likely decrease complications related to VKAs.
METHODS: Our study is prospective, descriptive, and longitudinal, including patients admitted to an Internal Medicine department in Tunis, during a 9-month period. One hundred patients diagnosed with VTE confirmed with imaging and treated with VKAs were included. TTR was calculated using Rosendaal's method through a free software INR PRO©.
RESULTS: The mean age of patients was 59.4 ± 16.7 years. Sex-ratio was 1.5. VKAs were mainly prescribed for deep venous thromboses (57%). Cancer was the most common etiology (26%). The mean follow-up period was 5.3 months. The mean TTR was 36.1±22.5%. Twenty-seven percent of patients had a TTR>50%. We noted 25% of hemorrhagic events and 15% of thromboembolic recurrence. A TTR<50% was correlated with hemorrhagic complications (p=0.02), but not with thrombotic ones (p = 0.224).
CONCLUSION: Our results outline the necessity of implementing adequate tools to improve anticoagulation in our population. Implementing TTR as a quality assessment tool for anticoagulation will likely decrease complications related to VKAs.